1. Home
  2. PHIO vs FEMY Comparison

PHIO vs FEMY Comparison

Compare PHIO & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.65

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

SELL

Current Price

$1.22

Market Cap

11.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PHIO
FEMY
Founded
2003
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
11.5M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
PHIO
FEMY
Price
$0.65
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $14.75
AVG Volume (30 Days)
53.7K
★ 104.8K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.71
EPS
★ N/A
N/A
Revenue
N/A
★ $2,293,313.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$294.61
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 40.77
52 Week Low
$0.70
$0.29
52 Week High
$1.88
$6.29

Technical Indicators

Market Signals
Indicator
PHIO
FEMY
Relative Strength Index (RSI) 27.10 36.99
Support Level N/A $0.33
Resistance Level $1.12 $1.55
Average True Range (ATR) 0.07 0.14
MACD -0.01 0.01
Stochastic Oscillator 5.14 36.46

Price Performance

Historical Comparison
PHIO
FEMY

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: